Michael Severino, MD
The phase III TAHOE trial (NCT03061812) evaluating second-line rovalpituzumab tesirine (Rova-T) as a treatment for patients with advanced small cell lung cancer (SCLC) has stopped enrollment as recommended by an Independent Data Monitoring Committee (IDMC), according to AbbVie, the developer of the investigational antibody-drug conjugate.1
Rova-T is also being evaluated in the phase III MERU trial (NCT03033511), which is looking at the antibody-drug conjugate as maintenance therapy following frontline platinum-based chemotherapy in patients with extensive-stage SCLC. In addition, phase I studies are also exploring Rova-T in combination with chemotherapy, nivolumab (Opdivo), and nivolumab plus ipilimumab (Yervoy).
- Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE Study) Halted. AbbVie. Published December 5, 2018. https://bit.ly/2KZcyVl. Accessed December 6, 2018.
- Carbone DP, Morgensztern D, Le Moulec S, et al. Efficacy and safety of rovalpituzumab tesirine (Rova-TTM) in patients with DLL3-expressing, ≥3rd line small cell lung cancer: results from the phase 2 TRINITY study. J Clin Oncol. 2018;36 (suppl; abstr 8507). doi: 10.1200/JCO.2018.36.15_suppl.8507.
... to read the full story